The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1617
ISSUE 1617
February 8, 2021
Avapritinib (Ayvakit) for GIST
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
February 8, 2021 (Issue: 1617)
The FDA has approved the oral tyrosine kinase
inhibitor avapritinib (Ayvakit – Blueprint Medicines)
for treatment of unresectable or metastatic gastrointestinal
stromal tumors (GISTs) harboring a
platelet-derived growth factor receptor alpha
(PDGFRA) D842V or other PDGFRA exon 18 mutation.
Avapritinib is the first drug to be approved for this
indication in the US.
... more
- V Indio et al. Integrated molecular characterization of gastrointestinal stromal tumors (GIST) harboring the rare D842V mutation in PDGFRA gene. Int J Mol Sci 2018; 19:732.
- K Akahoshi et al. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol 2018; 24:2806.
- S Farag et al. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. Curr Treat Options Oncol 2020; 21:55.
- Regorafenib (Stivarga) for metastatic colon cancer and GIST. Med Lett Drugs Ther 2013; 55:36.
- MC Heinrich et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumors (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 2020; 21:935.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2020 September 10 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. January 5, 2021. Reprinted with permission by First Databank, Inc. All rights reserved. ©2021. www.fdbhealth.com/drug-pricing-policy.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Avapritinib (Ayvakit) for GIST
Article code: 1617d
Electronic, downloadable article - $45
Article code: 1617d
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian